# Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes

> **NCT06759922** · PHASE4 · COMPLETED · sponsor: **Bahria University** · enrollment: 172 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Tab Metformin + Tab Glimepiride
- **DRUG:** Tab Metformin + Tab Empagliflozin
- **DRUG:** Tab Metformin +Tab Sitagliptin
- **DRUG:** Tab Metformin + Tab Empagliflozin + Tab Sitagliptin

## Key facts

- **NCT ID:** NCT06759922
- **Lead sponsor:** Bahria University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-01
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759922, "Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06759922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*